Neurogene Inc. Operating Lease, Expense
Neurogene Inc. (NGNE) reported Operating Lease, Expense of $385.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-11
- Neurogene Inc. operating lease, expense for the quarter ending 2026-06-30 was $195.00K, a 3.47% decline year-over-year.
- Neurogene Inc. operating lease, expense for the quarter ending 2026-03-31 was $190.00K, a 3.55% decline year-over-year.
- Neurogene Inc. operating lease, expense for the quarter ending 2025-12-31 was $194.00K, a 0.52% increase year-over-year.
- Neurogene Inc. operating lease, expense for the quarter ending 2025-09-30 was $207.00K, a 10.11% increase year-over-year.
- Neurogene Inc. operating lease, expense for fiscal 2025 was $800.00K, a 7.96% increase from fiscal 2024.
- Neurogene Inc. operating lease, expense for fiscal 2024 was $741.00K, a 11.76% increase from fiscal 2023.
- Neurogene Inc. operating lease, expense for fiscal 2023 was $663.00K, a 9.05% increase from fiscal 2022.
- Neurogene Inc. operating lease, expense for fiscal 2022 was $608.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $385.00K 10-Q · filed 2026-08-11 | $579.00K derived: sum of 3 quarters · filed 2026-08-11 | $786.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $190.00K 10-Q · filed 2026-05-12 | $384.00K derived: sum of 2 quarters · filed 2026-05-12 | $591.00K derived: sum of 3 quarters · filed 2026-05-12 | $793.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $401.00K derived: sum of 2 quarters · filed 2026-03-24 | $603.00K derived: sum of 3 quarters · filed 2026-08-11 | $800.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $207.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $409.00K derived: sum of 2 quarters · filed 2026-08-11 | $606.00K 10-Q · filed 2025-11-13 | $799.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $399.00K 10-Q · filed 2026-08-11 | $592.00K derived: sum of 3 quarters · filed 2026-08-11 | $780.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $197.00K 10-Q · filed 2026-05-12 | $390.00K derived: sum of 2 quarters · filed 2026-05-12 | $578.00K derived: sum of 3 quarters · filed 2026-05-12 | $762.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $193.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $381.00K derived: sum of 2 quarters · filed 2026-03-24 | $565.00K derived: sum of 3 quarters · filed 2026-03-24 | $741.00K 10-K · filed 2026-03-24 |
| 2024-09-30 | $188.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $372.00K derived: sum of 2 quarters · filed 2025-11-13 | $548.00K 10-Q · filed 2025-11-13 | $719.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $360.00K 10-Q · filed 2025-08-11 | $531.00K derived: sum of 3 quarters · filed 2025-08-11 | $699.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $176.00K 10-Q · filed 2025-05-09 | $347.00K derived: sum of 2 quarters · filed 2025-05-09 | $515.00K derived: sum of 3 quarters · filed 2025-05-09 | $679.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $339.00K derived: sum of 2 quarters · filed 2025-03-24 | $503.00K derived: sum of 3 quarters · filed 2025-03-24 | $663.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $332.00K derived: sum of 2 quarters · filed 2024-11-18 | $492.00K 10-Q · filed 2024-11-18 | |
| 2023-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $324.00K 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $160.00K 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $608.00K 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |